Evidence map›Paper›PMID 40722203›Full record

ArticleArthritis research & therapy2025

Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases.

Edgar Wiebe, Elisa Celine Schilling, Dörte Huscher, Andriko Palmowski, Zhivana Boyadzhieva, Sandra Hermann, Burkhard Muche, Mirella Lopez Picazo, Gerhard Krönke, Falk Hiepe and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Management of glucocorticoid-induced osteoporosis in rheumatic diseases.Best practice & research. Clinical rheumatology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Edgar WiebeCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany. edgar.wiebe@charite.de.
Elisa Celine SchillingCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Dörte HuscherCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charitéplatz 1, Berlin, 10117, Germany.
Andriko PalmowskiCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Zhivana BoyadzhievaCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Sandra HermannCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Burkhard MucheCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Mirella Lopez Picazo3D-SHAPER Medical, Rambla de Catalunya 53 4-H, 08007 Barcelona, Eixample, Spain.
Gerhard KrönkeCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Falk HiepeCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Tobias AlexanderCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.
Frank ButtgereitCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Chariteplatz 1, Berlin, 10117, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients with systemic lupus erythematosus (SLE) are at higher risk for osteoporosis and fragility fractures. Our study aimed to identify disease-specific factors with impact on bone mineral density (BMD) and the risk of osteoporosis, and to evaluate the effectiveness of DXA-derived 3D femur parameters versus BMD and trabecular bone score (TBS) in discriminating pre-existent fragility fractures.

methodsWe analyzed baseline data of a consecutive subcohort of patients with SLE with current or past GC treatment, fulfilling the EULAR/ACR 2019 SLE classification criteria. We used multivariable linear and logistic regression models to identify BMD- and osteoporosis-related factors. DXA-derived 3D measurements of the femur were performed with 3D-Shaper software. Discriminatory performance of BMD, TBS and 3D femoral parameters for fragility fractures was assessed by AUC values.

resultsForty-one percent of 110 patients with SLE had osteoporosis. Lupus nephritis (LN) was present in 35% of cases, with 61% (23/38) of these being predominantly classified as classes IV and V. Factors significantly associated with lower BMD included LN classes III and IV, U1-RNP antibodies, higher C-reactive protein, and longer disease duration. Clinical remission, higher Siglec-1 levels, higher body mass index, and higher health assessment questionnaire (HAQ) scores correlated positively with BMD. Osteoporosis was linked to LN, higher age, HAQ, and complement factor 3 levels. Our findings suggest that 3D bone structure analysis may be helpful in discriminating past vertebral fractures.

conclusionDisease severity indicated by LN, high CRP, presence of U1-RNP antibodies, and extended disease duration are detrimental to bone health. Moreover, 3D-DXA parameters can be integrated in clinical practise to assess bone health.

Indexed as

AutoantibodiesBone DensityLupus Erythematosus, SystemicLupus NephritisOsteoporosisRheumatic DiseasesRibonucleoprotein, U1 Small NuclearAbsorptiometry, PhotonAdultCohort StudiesFemaleHumansMaleMiddle AgedAutoantibodiesRibonucleoprotein, U1 Small NuclearFracture riskOsteoporosisRegistriesSystemic lupus erythematosus

Identifiers

PMID40722203
PMCPMC12305897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.